成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America >>article

Resistance to trimethoprim-sulfamethoxazole.

Published:1 June 2001 DOI: 10.1086/320532
G. Eliopoulos,?P. Huovinen

Abstract

Sulfonamides have a glorious history. In 1935, they were the first class of true antimicrobial agents with life-saving potency. Today, 66 years later, increased bacterial resistance to sulfonamides and to trimethoprim (TMP), a synthetic antimicrobial agent that is 30 years younger than sulfonamides, has limited their use to only a few indications. In the treatment and prophylaxis of patients with urinary tract infections, trimethoprim-sulfamethoxazole (TMP-SMZ) or TMP alone is still considered the first-line drug of choice, although increased bacterial resistance to these agents has been linked with treatment failure. TMP-SMZ has a possible role as a second- or third-line treatment for patients who have respiratory tract infections. In the developing world, where this inexpensive drug is widely used as first-line treatment, bacterial resistance has caused problems, especially with regard to the treatment of patients with severe respiratory tract infections. Use of TMP-SMZ as prophylaxis for Pneumocystis carinii infection has rapidly increased the multidrug resistance of bacterial pathogens found in human immunodeficiency virus-infected patients. Today, detailed and reliable knowledge on the resistance of bacterial pathogens to both TMP-SMZ and TMP is an essential requirement for the safe and effective use of these drugs in all clinical settings.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Sulfamethoxazole 723-46-6 C10H11N3O3S 661 suppliers $5.00-$683.00
Trimethoprim 738-70-5 C14H18N4O3 608 suppliers $6.00-$1330.00
Trimethyl phosphate 512-56-1 C3H9O4P 486 suppliers $19.00-$818.61

Similar articles

IF:4.1

Trimethoprim and sulfonamide resistance.

Antimicrobial Agents and Chemotherapy P Huovinen, L Sundstr?m,etc Published: 1 February 1995
IF:3.3

MOTS-c relieves hepatocellular carcinoma resistance to TRAIL-induced apoptosis under hypoxic conditions by activating MEF2A

Experimental cell research Haiying Shen, Junjie Nie,etc Published: 22 November 2024